Background: The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available. Objective: To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test. Methods: We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model. Results: Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002). Conclusion: Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.

SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study / Sormani, M. P.; Schiavetti, I.; Landi, D.; Carmisciano, L.; De Rossi, N.; Cordioli, C.; Moiola, L.; Radaelli, M.; Immovilli, P.; Capobianco, M.; Brescia Morra, V.; Trojano, M.; Tedeschi, G.; Comi, G.; Battaglia, M. A.; Patti, F.; Fragoso, Y. D.; Sen, S.; Siva, A.; Furlan, R.; Salvetti, M.; Abbadessa, G.; Aguglia, U.; Allegorico, L.; Allegri, R. B. M.; Amato, M. P.; Annovazzi, P.; Antozzi, C.; Appendino, L.; Arena, S.; Baione, V.; Balgera, R.; Barcella, V.; Baroncini, D.; Barrila, C.; Battaglia, M. A.; Bellacosa, A.; Bellucci, G.; Bergamaschi, R.; Bergamaschi, V.; Bezzini, D.; Biolzi, B.; Bisecco, A.; Bonavita, S.; Borriello, G.; Bosa, C.; Bosco, A.; Bovis, F.; Bozzali, M.; Brambilla, L.; Brescia, M. V.; Brichetto, G.; Buccafusca, M.; Bucciantini, E.; Bucello, S.; Buscarinu, M. C.; Cabboi, M. P.; Calabrese, M.; Calabria, F.; Caleri, F.; Camilli, F.; Caniatti, L. M.; Cantello, R.; Capobianco, M.; Capra, R.; Capuano, R.; Carmisciano, L.; Carta, P.; Cavalla, P.; Celani, M. G.; Cellerino, M.; Cerqua, R.; Chisari, C.; Clerici, R.; Clerico, M.; Cocco, E.; Cola, G.; Comi, G.; Confalonieri, P.; Conte, A.; Conti, M. Z.; Cordano, C.; Cordera, S.; Cordioli, C.; Corea, F.; Correale, C.; Cottone, S.; Crescenzo, F.; Curti, E.; d'Ambrosio, A.; D'Amico, E.; Danni, M. C.; d'Arma, A.; Dattola, V.; de Biase, S.; De Luca, G.; De Mercanti, S. F.; De Mitri, P.; De Rossi, N.; De Stefano, N.; Della Cava, M.; di Napoli, M.; Di Sapio, A.; Docimo, R.; Dutto, A.; Evangelista, L.; Fanara, S.; Ferraro, D.; Ferro, M. T.; Filippi, M.; Fioretti, C.; Fratta, M.; Frau, J.; Fronza, M.; Furlan, R.; Gajofatto, A.; Gallo, A.; Gallo, P.; Gasperini, C.; Ghazaryan, A.; Giometto, B.; Gobbin, F.; Govone, F.; Granella, F.; Grange, E.; Grasso, M. G.; Guareschi, A.; Guaschino, C.; Guerrieri, S.; Guidetti, D.; Iaffaldano, P.; Ianniello, A.; Iasevoli, L.; Immovilli, P.; Imperiale, D.; Infante, M. T.; Inglese, M.; Iodice, R.; Iovino, A.; Konrad, G.; Landi, D.; Lanzillo, R.; Lapucci, C.; Lavorgna, L.; L'Episcopo Maria, R.; Leva, S.; Liberatore, G.; Lo Re, M.; Longoni, M.; Lopiano, L.; Lorefice, L.; Lucchini, M.; Lus, G.; Maimone, D.; Malentacchi, M.; Mallucci, G.; Malucchi, S.; Mancinelli, C. R.; Mancinelli, L.; Manganotti, P.; Maniscalco, T. G.; Mantero, V.; Marangoni, S.; Marastoni, D.; Marfia, A. G.; Marinelli, F.; Marti, A.; Martinelli Boneschi, F.; Masserano Zoli, F.; Matta, F.; Mendozzi, L.; Meucci, G.; Miante, S.; Miele, G.; Milano, E.; Mirabella, M.; Missione, R.; Moccia, M.; Moiola, L.; Montepietra, S.; Monti Bragadin, M.; Montini, F.; Motta, R.; Nardone, R.; Nicoletti, C. G.; Nobile-Orazio, E.; Nozzolillo, A.; Onofrj, M.; Orlandi, R.; Palmieri, A.; Paolicelli, D.; Pasquali, L.; Pasto, L.; Patti, F.; Pedrazzoli, E.; Perini, P.; Pesci, I.; Petracca, M.; Petrone, A.; Piantadosi, C.; Pietroboni, A. M.; Pinardi, F.; Ponzano, M.; Portaccio, E.; Pozzato, M.; Pozzilli, C.; Prosperini, L.; Protti, A.; Radaelli, M.; Ragonese, P.; Rasia, S.; Realmuto, S.; Repice, A.; Rigoni, E.; Rilla, M. T.; Rinaldi, F.; Romano, C. M.; Ronzoni, M.; Rovaris, M.; Ruscica, F.; Sabattini, L.; Salemi, G.; Salvetti, M.; Saraceno, L.; Sartori, A.; Sartori, A.; Sbragia, E.; Scandellari, C.; Scarano Giuditta, I.; Scarano, V.; Schiavetti, I.; Schillaci, V.; Sessa, M.; Sgarito, C.; Sibilia, G.; Siciliano, G.; Signori, A.; Signoriello, E.; Sinisi, L.; Sireci, F.; Sola, P.; Solaro, C.; Sormani, M. P.; Sotgiu, S.; Sparaco, M.; Stromillo, M. L.; Strumia, S.; Susani, L. E.; Tabiadon, G.; Teatini, F.; Tedeschi, G.; Tomassini, V.; Tonietti, S.; Torri, C. V.; Tortorella, C.; Toscano, S.; Totaro, R.; Trojano, M.; Trotta, M.; Turano, G.; Ulivelli, M.; Valentino, M.; Vaula, G.; Vecchio, D.; Vercellino, M.; Verrengia, E. P.; Vianello, M.; Virgilio, E.; Vitetta, F.; Vollaro, S.; Zaffaroni, M.; Zampolini, M.; Zarbo, I. R.; Zito, A.; Zuliani, L.. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - 28:7(2022), pp. 1034-1040. [10.1177/13524585211035318]

SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Salvetti M.
;
Baione V.;Bellucci G.;Buscarinu M. C.;Conte A.;Gasperini C.;Ianniello A.;Petracca M.;Pozzilli C.;Prosperini L.;Salvetti M.;Tomassini V.;
2022

Abstract

Background: The MuSC-19 project is an Italian cohort study open to international partners that collects data on multiple sclerosis (MS) patients with COVID-19. During the second wave of the pandemic, serological tests became routinely available. Objective: To evaluate the seroprevalence of anti-SARS-CoV-2 antibodies according to the use of disease-modifying therapy (DMT) in a subset of patients included in the MuSC-19 data set who had undergone a serological test. Methods: We evaluated the association between positive serological test results and time elapsed since infection onset, age, sex, Expanded Disability Status Scale score, comorbidities and DMT exposure using a multivariable logistic model. Results: Data were collected from 423 patients (345 from Italy, 61 from Turkey and 17 from Brazil) with a serological test performed during follow-up. Overall, 325 out of 423 tested patients (76.8%) had a positive serological test. At multivariate analysis, therapy with anti-CD20 was significantly associated with a reduced probability of developing antibodies after COVID-19 (odds ratio (OR) = 0.20, p = 0.002). Conclusion: Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.
File allegati a questo prodotto
File Dimensione Formato  
Ponzano_A multiparametric score_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 531.63 kB
Formato Adobe PDF
531.63 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1639499
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 22
social impact